No Data
No Data
Bio-Thera Solutions' Betanin Gets Marketing Green Light From Chinese Drug Regulator
Bio-Thera Solutions' (SHA:688177) bevibatide citrate injection obtained a drug registration certificate from Chinese drug regulator National Medical Products Administration, according to the company's
Bio-Thera Solutions (688177.SH): TOFIDENCE receives market approval from the European Commission.
Bio-Thera Solutions (688177.SH) announced that its partner, Biogen International GmbH ("Biogen"), has recently received notice from the European Commission that TOFIDENCE (BAT1806, tocilizumab injection) has been approved for marketing by the European Commission for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.
Bio-Thera Solutions (688177.SH) received a government subsidy of 41.4193 million yuan.
Bio-Thera Solutions (688177.SH) announced on June 5th that from January 1, 2024 to the date of this announcement, the company has received a cumulative government subsidy of RMB 41,419,300, of which RMB 26,419,300 is related to revenue and RMB 15,000,000 is related to assets.
Bio-Thera Solutions (688177.SH): Therabio and Fanwan Lake plan to reduce their shareholdings by a total of no more than 2% through bulk trading.
On June 4th, Gelunhui reported that Bio-Thera Solutions (688177.SH) announced that Therabio and Wanwan Lake plan to reduce their holdings of the company's shares through block trades due to their own capital arrangement needs, with a total of no more than 8,281,600 shares (including this number), accounting for no more than 2% of the total share capital of the company, under the premise of complying with laws and regulations. The block trades will be conducted within 3 months after 15 trading days from the date of this announcement, and the total number of shares sold during any consecutive 90 days shall not exceed 2% of the company's total share capital. If there are restrictions on the window period for buying and selling stocks during the reduction period, the share reduction will be stopped.
Express News | Bio-Thera Solutions Receives Positive Chmp Opinion for Avzivi® (Bevacizumab), a Biosimilar Referencing Avastin®
Bio-Thera Solutions (688177.SH): Avzivi (bevacizumab injection) received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
On June 3, Gelonhui reported that Bio-Thera Solutions (stock code 688177.SH) has recently received a notice from the European Medicines Agency (EMA) that Avzivi (BAT1706, bevacizumab injection) has received positive opinions from the EMA Committee for Medicinal Products for Human Use (CHMP). CHMP recommended that the European Commission approve the launch of Avzivi for the treatment of metastatic colorectal cancer, metastatic breast cancer, non-small cell lung cancer, metastatic renal cell carcinoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and metastatic cervical cancer.
No Data